Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population

Jolien J. M. Freriksen; Joyce E. M. van der Heijden; Marika A. de Hoop-Sommen; Rick Greupink; Saskia N. de Wildt

doi:10.1007/s40272-022-00535-w

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population

Jolien J. M. Freriksen^*, Joyce E. M. van der Heijden, Marika A. de Hoop-Sommen, Rick Greupink, Saskia N. de Wildt

^*Corresponding author for this work

Pediatric Surgery

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

13 Downloads (Pure)

Abstract

Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to increase the evidence base of pediatric drug dosing recommendations by making optimal use of existing pharmacokinetic (PK) data. A pragmatic approach of combining available compound models with a virtual pediatric physiology model can be a rational solution to predict PK and hence support dosing guidelines for children in real-life clinical care, when it can also be employed by individuals with little experience in PBPK modeling. This comes within reach as user-friendly PBPK modeling platforms exist and, for many drugs and populations, models are ready for use. We have identified a list of drugs that can serve as a starting point for pragmatic PBPK modeling to address current clinical dosing needs.

Original language	English
Pages (from-to)	5-11
Number of pages	7
Journal	Paediatric Drugs
Volume	25
Issue number	1
Early online date	6 Oct 2022
DOIs	https://doi.org/10.1007/s40272-022-00535-w
Publication status	Published - Jan 2023

Bibliographical note

Funding Information:
This publication is based on research funded by the Bill & Melinda Gates Foundation (Grant number: INV-001822). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.

Publisher Copyright:
© 2022, The Author(s).

Access to Document

10.1007/s40272-022-00535-wLicence: CC BY-NC

s40272-022-00535-wFinal published version, 733 KBLicence: CC BY-NC

Cite this

@article{dcc83123591c4b26b9596e56bd8b57ee,

title = "Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population",

abstract = "Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to increase the evidence base of pediatric drug dosing recommendations by making optimal use of existing pharmacokinetic (PK) data. A pragmatic approach of combining available compound models with a virtual pediatric physiology model can be a rational solution to predict PK and hence support dosing guidelines for children in real-life clinical care, when it can also be employed by individuals with little experience in PBPK modeling. This comes within reach as user-friendly PBPK modeling platforms exist and, for many drugs and populations, models are ready for use. We have identified a list of drugs that can serve as a starting point for pragmatic PBPK modeling to address current clinical dosing needs.",

author = "Freriksen, {Jolien J. M.} and {van der Heijden}, {Joyce E. M.} and {de Hoop-Sommen}, {Marika A.} and Rick Greupink and {de Wildt}, {Saskia N.}",

note = "Funding Information: This publication is based on research funded by the Bill & Melinda Gates Foundation (Grant number: INV-001822). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2023",

month = jan,

doi = "10.1007/s40272-022-00535-w",

language = "English",

volume = "25",

pages = "5--11",

journal = "Paediatric Drugs",

issn = "1174-5878",

publisher = "Adis",

number = "1",

}

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population. / Freriksen, Jolien J. M.; van der Heijden, Joyce E. M.; de Hoop-Sommen, Marika A. et al.
In: Paediatric Drugs, Vol. 25, No. 1, 01.2023, p. 5-11.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care

T2 - A Pragmatic Approach for a Special Population

AU - Freriksen, Jolien J. M.

AU - van der Heijden, Joyce E. M.

AU - de Hoop-Sommen, Marika A.

AU - Greupink, Rick

AU - de Wildt, Saskia N.

N1 - Funding Information: This publication is based on research funded by the Bill & Melinda Gates Foundation (Grant number: INV-001822). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. Publisher Copyright: © 2022, The Author(s).

PY - 2023/1

Y1 - 2023/1

N2 - Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to increase the evidence base of pediatric drug dosing recommendations by making optimal use of existing pharmacokinetic (PK) data. A pragmatic approach of combining available compound models with a virtual pediatric physiology model can be a rational solution to predict PK and hence support dosing guidelines for children in real-life clinical care, when it can also be employed by individuals with little experience in PBPK modeling. This comes within reach as user-friendly PBPK modeling platforms exist and, for many drugs and populations, models are ready for use. We have identified a list of drugs that can serve as a starting point for pragmatic PBPK modeling to address current clinical dosing needs.

AB - Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to increase the evidence base of pediatric drug dosing recommendations by making optimal use of existing pharmacokinetic (PK) data. A pragmatic approach of combining available compound models with a virtual pediatric physiology model can be a rational solution to predict PK and hence support dosing guidelines for children in real-life clinical care, when it can also be employed by individuals with little experience in PBPK modeling. This comes within reach as user-friendly PBPK modeling platforms exist and, for many drugs and populations, models are ready for use. We have identified a list of drugs that can serve as a starting point for pragmatic PBPK modeling to address current clinical dosing needs.

UR - http://www.scopus.com/inward/record.url?scp=85139496539&partnerID=8YFLogxK

U2 - 10.1007/s40272-022-00535-w

DO - 10.1007/s40272-022-00535-w

M3 - Article

C2 - 36201128

SN - 1174-5878

VL - 25

SP - 5

EP - 11

JO - Paediatric Drugs

JF - Paediatric Drugs

IS - 1

ER -

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this